METHODS: 44 cases were analyzed that are surgically operated with robot-assisted radical prostatectomy performed from February to September in 2016. Preoperative MRI have been conducted for all 44 cases, and the prostate cancer local diagnoses (Region of Interest: ROI) were determined by radiologists using MRI T2 weighed image and Diffusion Weighed Image (DWI), then finally the scores of ADC were calculated. IHC for aSMA, vimentin, CD105, and Tenascin-C (TNC-C) were conducted and classified into three group (none stained, weakly stained, strongly stained) to check the relation of those IHC findings to MRI ADC score before the treatment.
INTRODUCTION AND OBJECTIVES:
The efficacy of various next-generation antiandrogens for CRPC is limited. In this study, we investigated gene expression profiles of CRPC cells with AR knockdown using microarray, and identified candidate drugs for overcoming CRPC through degrading AR splice variants.
METHODS: Three cell lines were used: LNCaP, a human PCa cell line that exhibits androgen-dependent proliferation; C4-2AT6, an androgenindependent CRPC cell line; and 22Rv1 an AR-V7 positive CRPC cell line. Gene expression change by AR knockdown in CRPC cells were analyzed using a microarray and compared using CMAP to identify a candidate drug with the potential to have AR degradation effect similar to AR knockdown. The efficacy of the candidate drug was tested in vitro and in vivo.
RESULTS: We investigated and compared the viability of prostate cancer cells treated with DHT. DHT promoted LNCaP cells proliferation in dose dependent manner. On the other hand, C4-2AT6 cells showed significantly decreased cell viability when treated with DHT. We next perform AR knockdown by SiRNA to LNCaP and C4-2AT6. In WST assay, relative cell viability after AR knockdown was 46.9 % AE 2.7 % and 44.1 AE 2.0 %, respectively. These results suggested that C4-2AT6 depended on AR signaling while it had androgen independence We explored candidate drugs which mimicked AR knockdown to C4-2AT6 by CMAP analysis. We identified a candidate compound for degrading AR in CRPC, AHG113. The cytotoxic effect of AHG113 was investigated by a cell viability assay in LNCaP and C4-2AT6 cells; relative cell viability when treated with 10 mM AHG113 was 79.2 AE 1.1 % and 67.5 AE 1.9 %, respectively. AHG113 was suggested to have higher cytotoxicity to CRPC than androgen dependent PCa (p ¼ 0.002). Western blotting demonstrated AHG113 degrade AR protein in C4-2AT6. Because AR-V7 was focused as a next-generation antiandrogens resistance mechanism, we investigated AR-V7 degradation effect of AHG113. Western blotting and flow cytometry demonstrated AHG113 degraded both AR full length and AR-V7 in 22Rv1. We administered AHG113 to 22Rv1 xenograft mice for investigating anti-tumor effect in vivo. AHG113 significantly inhibited xenograft tumor growth (p < 0.001). Immunohistochemistry of xenograft tumor demonstrated AHG113 reduced AR-V7 expression.
CONCLUSIONS: AHG113 may be promising drug for overcoming androgen-independent and AR-V7 positive CRPC.
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MP64-07 VASCULAR HURST INDEX IN NON-TUMORAL BIOPSY CORES AS POTENTIAL HISTOPATHOLOGICAL PARAMETER TO SELECT PATIENTS WITH HIDDEN PROSTATE CANCER
INTRODUCTION AND OBJECTIVES: It's accepted that angiogenesis is a complex phenomenon accompanying the development, progression and metastasis of tumors of unrelated histological origin. We introduce the Hurst index to investigate the two-dimensional (2-D) geometrical complexity of the tumor vascular network in biopsy specimens to comprehend whether non-tumoral biopsy cores might be helpful to select patients with hidden prostate cancer.
METHODS: 1984 biopsy cores sampled from a total of 316 patients were analyzed. Patients were categorized in two main groups: a) Prostate Cancer Group: 140 patients with first positive biopsies for prostate cancer and 60 patients negative for prostate cancer at first biopsy and positive at re-biopsy. b) e852 THE JOURNAL OF UROLOGY â Vol. 199, No. 4S, Supplement, Sunday, May 20, 2018 
